Navigation Links
KaloBios' KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Date:9/18/2013

underway of KB001-A as a potential non-antibiotic treatment to reduce airway inflammation and tissue damage in CF patients with chronic Pa infection," Dr. Molfino concluded.

The published study results showed a single intravenous dose of KB001 to have an acceptable safety profile and a trend toward a short-term reduction in markers of inflammation, particularly neutrophil elastase which has long been recognized as the main enzyme responsible for lung damage in CF patients. The investigators concluded that repeat-dosing studies are required to evaluate the durability of the anti-inflammatory effects and how treatment with KB001 might translate into clinical benefit.

KaloBios is currently enrolling patients in a Phase 2 multi-dose, randomized, double-blind, placebo-controlled clinical trial with KB001-A in CF patients chronically infected with Pa. This 180-patient study is intended to evaluate the efficacy and safety of repeat doses of KB001-A. The primary endpoint is time-to-need for antibiotics. To learn more about this study, including eligibility criteria, please visit www.clinicaltrials.gov.

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

Currently, KaloBios has three drug development programs:

  • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a planned 150 patient Phase 2 study in the United States, Europe and Australia
    '/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
8. KaloBios to Present at Needham Healthcare Conference
9. KaloBios Reports First Quarter 2013 Financial Results
10. KaloBios to Present at Stifel Healthcare Conference 2013
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Calif. , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on ... ("SEC") by Mallinckrodt plc on May 16, 2014 and amended ... of Mallinckrodt and Questcor that also constitutes a prospectus of ... statement on Form S-4 is available on the SEC,s EDGAR ...
(Date:7/14/2014)... 2014 BioAdaptives, Inc. (OTCBB:BDPT) is pleased to ... the roles of President and CEO of the Company.  ... the company that licensed its formulation, intellectual properties, and ... "Mr. Gerald Epling , who ... a privately held entity to a public company, has ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7BioAdaptives Prepares for Next Step 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3
... Aug. 5, 2011 Varian Medical Systems, Inc. (NYSE: ... former CEO and member of the Board of Directors for ... of management in global medical device businesses, has been appointed ... Varian,s Board of Directors also increased its size from nine ...
... FOREST, Ill., Aug. 5, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... presentations include 200 mg, 1 gm and 2 gm with ... sales of more than $750 million in 2010, led by ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 2Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 3
(Date:7/14/2014)... Sunrise, FL (PRWEB) July 14, 2014 ... announced the expansion of its Quality Control and Assurance ... Formulations has hired two additional, highly-qualified quality assurance (QA) ... superior product standards for which IQ Formulations has become ... and QC technicians bring decades of stellar experience and ...
(Date:7/14/2014)... 2014 Secure Decisions, a leading provider ... with the Software Assurance Marketplace (SWAMP) to build a ... that drives everyday life. , The SWAMP, implemented by ... the Morgridge Institute for Research, is funded by the ... security practices by building a free facility with a ...
(Date:7/14/2014)... HealthDay Reporter SUNDAY, July ... a faltering sense of smell might signal the early ... smell test could spot who needs more extensive screening ... ability to identify odors was associated with the loss ... "We,re trying to be able to diagnose Alzheimer,s ...
(Date:7/14/2014)... 14, 2014 Follow ... liquid chromatography or UPLC is a new ... chromatography that involves the use of extremely ... separate chromatographic compounds. This highly sensitive qualitative ... and analysis of chromatography samples. UPLC functions ...
(Date:7/14/2014)... Francisco, California (PRWEB) July 14, 2014 ... expected to reach USD 4,285.1 million by 2020 ... a new study by Grand View Research, Inc. ... computational biology for bioinformatics R&D programs designed for ... increasing number of clinical studies in pharmacogenomics and ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6
... 7- to ... 9-hour flights, HOBOKEN, N.J., Nov. ... Pycnogenol(R), pine bark,extract from the French maritime pine tree, reduces jetlag in ... scan and a,scoring system, showed Pycnogenol(R) lowered symptoms of jetlag such as,fatigue, ...
... N.J., Nov. 5 BD (Becton,Dickinson and Company) (NYSE: ... for the fourth fiscal quarter ended September 30, 2008,representing ... period. This,quarter,s growth rate reflects the favorable impact on ... to account for 5,percentage points of the increase in ...
... Simulation and Education Conference (I/ITSEC) has sold ... County Convention Center in Orlando. Occupying almost 200,000 ... modeling and simulation technology ever. The I/ITSEC ... 2008 at the Orange County Convention Center in ...
... qualified health insurance underwriters, much of the frustration associated with filling ... serve to not only comfort users, but expedite the entire process, ... ... CA (PRWEB) November 5, 2008 -- Internet based insurance agency, TheHealthQuote, ...
... review outlines potential pharmaceutical, dietary, surgical, and other ... among women in the United States, and examines ... risk reduction strategies for women at average risk ... factors. Among the recommendations: aside from following general ...
... six hours of,deliberation, a Broward County Jury awarded a ... secondhand exposure case. Lynda and Michael Daly,claimed that Mrs. ... asbestos-containing brakes manufactured by Ford Motor Co. and,Pneumo Abex. ... was diagnosed in,May of 2007 and has been a ...
Cached Medicine News:Health News:Study Shows Pine Bark Reduces Jetlag 2Health News:Study Shows Pine Bark Reduces Jetlag 3Health News:Study Shows Pine Bark Reduces Jetlag 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 2Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 3Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 5Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 6Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 7Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 8Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 9Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 10Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 11Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 12Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 13Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 14Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 2Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 3Health News:Customers Now Able to Receive Real Time, Online Assistance during Health Insurance Quote Process 2Health News:Customers Now Able to Receive Real Time, Online Assistance during Health Insurance Quote Process 3
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
For proper plug sizing....
Contour Design Eyelid Implants....
For Frontalis Suspension in patients with significant ptosis and poor levator function....
Medicine Products: